Jose Romero
Concepts (176)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cerebral Small Vessel Diseases | 6 | 2024 | 7 | 3.820 |
Why?
| Stroke | 13 | 2023 | 478 | 2.850 |
Why?
| Dementia | 3 | 2024 | 113 | 2.260 |
Why?
| Magnetic Resonance Imaging | 15 | 2024 | 1525 | 1.330 |
Why?
| Cerebral Hemorrhage | 9 | 2023 | 97 | 1.200 |
Why?
| Brain | 9 | 2024 | 1310 | 0.930 |
Why?
| Alzheimer Disease | 2 | 2022 | 283 | 0.800 |
Why?
| Cerebral Amyloid Angiopathy | 4 | 2023 | 4 | 0.720 |
Why?
| Hypertension | 2 | 2020 | 531 | 0.510 |
Why?
| Thrombolytic Therapy | 3 | 2020 | 110 | 0.500 |
Why?
| Humans | 39 | 2024 | 49898 | 0.470 |
Why?
| Longitudinal Studies | 6 | 2022 | 693 | 0.470 |
Why?
| Risk Factors | 14 | 2024 | 3604 | 0.440 |
Why?
| Brain Ischemia | 3 | 2020 | 157 | 0.430 |
Why?
| Tick-Borne Diseases | 1 | 2012 | 5 | 0.410 |
Why?
| Aged | 17 | 2024 | 9447 | 0.400 |
Why?
| Parechovirus | 1 | 2011 | 2 | 0.370 |
Why?
| Anti-Bacterial Agents | 3 | 2017 | 742 | 0.370 |
Why?
| Viral Vaccines | 1 | 2011 | 12 | 0.370 |
Why?
| Picornaviridae Infections | 1 | 2011 | 18 | 0.360 |
Why?
| Respiratory Syncytial Virus Infections | 1 | 2010 | 34 | 0.360 |
Why?
| Antibodies, Viral | 1 | 2011 | 93 | 0.360 |
Why?
| Respiratory Sounds | 1 | 2010 | 48 | 0.360 |
Why?
| Male | 22 | 2024 | 25437 | 0.350 |
Why?
| RNA, Viral | 1 | 2011 | 124 | 0.350 |
Why?
| Female | 23 | 2024 | 26560 | 0.350 |
Why?
| Respiratory Tract Infections | 1 | 2010 | 76 | 0.340 |
Why?
| Infant, Premature, Diseases | 1 | 2010 | 93 | 0.340 |
Why?
| Genome-Wide Association Study | 3 | 2023 | 163 | 0.310 |
Why?
| Pneumonia, Viral | 2 | 2020 | 170 | 0.280 |
Why?
| Coronavirus Infections | 2 | 2020 | 179 | 0.280 |
Why?
| Cohort Studies | 7 | 2021 | 1403 | 0.250 |
Why?
| Tissue Plasminogen Activator | 3 | 2021 | 110 | 0.250 |
Why?
| Motor Cortex | 2 | 2002 | 11 | 0.250 |
Why?
| Middle Aged | 12 | 2024 | 12285 | 0.230 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2023 | 3 | 0.230 |
Why?
| Incidence | 6 | 2021 | 986 | 0.230 |
Why?
| Sex Characteristics | 1 | 2024 | 191 | 0.210 |
Why?
| Basal Ganglia | 1 | 2023 | 23 | 0.210 |
Why?
| Infarction | 1 | 2022 | 14 | 0.210 |
Why?
| Fibrinolytic Agents | 2 | 2021 | 125 | 0.210 |
Why?
| Plaque, Atherosclerotic | 1 | 2022 | 39 | 0.200 |
Why?
| Carotid Stenosis | 1 | 2022 | 64 | 0.200 |
Why?
| Mental Health | 1 | 2024 | 218 | 0.200 |
Why?
| Electromagnetic Fields | 1 | 2002 | 16 | 0.200 |
Why?
| Early Medical Intervention | 1 | 2020 | 8 | 0.180 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2020 | 17 | 0.180 |
Why?
| Ischemic Attack, Transient | 1 | 2021 | 56 | 0.180 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2021 | 105 | 0.180 |
Why?
| Atherosclerosis | 1 | 2023 | 210 | 0.180 |
Why?
| Neurology | 1 | 2020 | 36 | 0.180 |
Why?
| Asymptomatic Diseases | 1 | 2020 | 36 | 0.180 |
Why?
| Iron | 1 | 2021 | 123 | 0.180 |
Why?
| Cardiovascular Diseases | 2 | 2023 | 444 | 0.180 |
Why?
| Data Interpretation, Statistical | 1 | 2020 | 159 | 0.170 |
Why?
| Radiography, Interventional | 1 | 2020 | 57 | 0.170 |
Why?
| Societies, Medical | 1 | 2020 | 177 | 0.170 |
Why?
| tau Proteins | 1 | 2019 | 22 | 0.170 |
Why?
| Aged, 80 and over | 7 | 2021 | 3136 | 0.170 |
Why?
| Venous Thrombosis | 1 | 2020 | 88 | 0.170 |
Why?
| Needs Assessment | 1 | 2020 | 133 | 0.170 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 137 | 0.160 |
Why?
| Recombinant Fusion Proteins | 1 | 2010 | 186 | 0.160 |
Why?
| Risk Assessment | 2 | 2020 | 1254 | 0.160 |
Why?
| Health Services Needs and Demand | 1 | 2020 | 154 | 0.160 |
Why?
| Angiogenesis Inhibitors | 1 | 2010 | 182 | 0.160 |
Why?
| Papillomavirus Vaccines | 1 | 2019 | 67 | 0.150 |
Why?
| Pharmacies | 1 | 2019 | 60 | 0.150 |
Why?
| Community Pharmacy Services | 1 | 2019 | 67 | 0.150 |
Why?
| Pneumococcal Infections | 1 | 2017 | 8 | 0.150 |
Why?
| Pneumococcal Vaccines | 1 | 2017 | 9 | 0.150 |
Why?
| Streptococcus pneumoniae | 1 | 2017 | 22 | 0.150 |
Why?
| Endovascular Procedures | 1 | 2020 | 176 | 0.140 |
Why?
| Arthritis, Infectious | 1 | 2017 | 46 | 0.140 |
Why?
| Stroke, Lacunar | 1 | 2016 | 1 | 0.140 |
Why?
| Prevalence | 1 | 2020 | 956 | 0.140 |
Why?
| Papillomavirus Infections | 1 | 2019 | 167 | 0.140 |
Why?
| Emotions | 1 | 2017 | 164 | 0.130 |
Why?
| Osteomyelitis | 1 | 2017 | 125 | 0.130 |
Why?
| Antibodies, Monoclonal | 1 | 2010 | 457 | 0.130 |
Why?
| Retrospective Studies | 6 | 2022 | 6123 | 0.130 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 450 | 0.130 |
Why?
| United States | 5 | 2020 | 4878 | 0.120 |
Why?
| Stenotrophomonas maltophilia | 1 | 2014 | 6 | 0.120 |
Why?
| Gram-Negative Bacterial Infections | 1 | 2014 | 42 | 0.120 |
Why?
| Leptin | 1 | 2015 | 137 | 0.120 |
Why?
| Meningitis, Meningococcal | 1 | 2013 | 3 | 0.110 |
Why?
| Meningococcal Infections | 1 | 2013 | 3 | 0.110 |
Why?
| Child, Preschool | 4 | 2020 | 3875 | 0.110 |
Why?
| Cross-Sectional Studies | 3 | 2024 | 1573 | 0.110 |
Why?
| RNA-Directed DNA Polymerase | 1 | 2002 | 6 | 0.100 |
Why?
| Oligodeoxyribonucleotides | 1 | 2002 | 31 | 0.100 |
Why?
| Bacteremia | 1 | 2013 | 90 | 0.100 |
Why?
| Infant | 4 | 2017 | 3572 | 0.100 |
Why?
| Evoked Potentials, Motor | 2 | 2002 | 7 | 0.100 |
Why?
| Amyloid beta-Peptides | 2 | 2023 | 58 | 0.100 |
Why?
| Neutrophils | 1 | 2013 | 148 | 0.100 |
Why?
| DNA, Complementary | 1 | 2002 | 134 | 0.100 |
Why?
| Tularemia | 1 | 2012 | 20 | 0.100 |
Why?
| Ehrlichiosis | 1 | 2012 | 14 | 0.100 |
Why?
| Brain Infarction | 2 | 2022 | 12 | 0.100 |
Why?
| Lyme Disease | 1 | 2012 | 32 | 0.100 |
Why?
| Antineoplastic Agents | 1 | 2010 | 1175 | 0.100 |
Why?
| Pandemics | 3 | 2020 | 566 | 0.090 |
Why?
| Upper Extremity Deep Vein Thrombosis | 1 | 2011 | 3 | 0.090 |
Why?
| Embolism, Paradoxical | 1 | 2011 | 3 | 0.090 |
Why?
| Intracranial Embolism | 1 | 2011 | 27 | 0.090 |
Why?
| Foramen Ovale, Patent | 1 | 2011 | 27 | 0.090 |
Why?
| Administration, Intravenous | 2 | 2020 | 70 | 0.090 |
Why?
| Mycobacterium tuberculosis | 1 | 2002 | 287 | 0.090 |
Why?
| Adult | 6 | 2021 | 13346 | 0.080 |
Why?
| Massachusetts | 2 | 2019 | 25 | 0.080 |
Why?
| Prospective Studies | 3 | 2020 | 2345 | 0.080 |
Why?
| Anticoagulants | 2 | 2021 | 253 | 0.070 |
Why?
| Infant, Premature | 1 | 2010 | 315 | 0.070 |
Why?
| Infant, Newborn | 2 | 2014 | 2729 | 0.070 |
Why?
| Severity of Illness Index | 1 | 2010 | 953 | 0.070 |
Why?
| Arkansas | 1 | 2012 | 1987 | 0.070 |
Why?
| Treatment Outcome | 3 | 2020 | 5176 | 0.060 |
Why?
| Child | 4 | 2020 | 6844 | 0.060 |
Why?
| Case-Control Studies | 2 | 2020 | 1128 | 0.060 |
Why?
| Young Adult | 3 | 2020 | 4029 | 0.060 |
Why?
| Electromyography | 2 | 2002 | 131 | 0.060 |
Why?
| Methyltransferases | 1 | 2023 | 29 | 0.060 |
Why?
| Constriction, Pathologic | 1 | 2022 | 95 | 0.050 |
Why?
| Carotid Arteries | 1 | 2022 | 82 | 0.050 |
Why?
| Adolescent | 3 | 2020 | 6414 | 0.050 |
Why?
| Sex Factors | 1 | 2024 | 691 | 0.050 |
Why?
| Blood Pressure | 1 | 2024 | 519 | 0.050 |
Why?
| Antihypertensive Agents | 1 | 2023 | 124 | 0.050 |
Why?
| Nerve Net | 1 | 2002 | 66 | 0.050 |
Why?
| Endothelial Cells | 1 | 2023 | 256 | 0.050 |
Why?
| Genomics | 1 | 2023 | 284 | 0.050 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2023 | 482 | 0.050 |
Why?
| Atrophy | 1 | 2020 | 38 | 0.050 |
Why?
| Neuroimaging | 1 | 2021 | 86 | 0.050 |
Why?
| Polysomnography | 1 | 2020 | 70 | 0.050 |
Why?
| Genetic Predisposition to Disease | 1 | 2023 | 507 | 0.040 |
Why?
| Boston | 1 | 2020 | 12 | 0.040 |
Why?
| Endocrine System Diseases | 1 | 2010 | 10 | 0.040 |
Why?
| Fluid Therapy | 1 | 2020 | 75 | 0.040 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 22 | 0.040 |
Why?
| Critical Pathways | 1 | 2020 | 37 | 0.040 |
Why?
| Vascular Diseases | 1 | 2020 | 74 | 0.040 |
Why?
| Triage | 1 | 2020 | 61 | 0.040 |
Why?
| Thrombectomy | 1 | 2020 | 69 | 0.040 |
Why?
| Brain Mapping | 1 | 2020 | 227 | 0.040 |
Why?
| Skin Diseases | 1 | 2010 | 114 | 0.040 |
Why?
| Gastrointestinal Diseases | 1 | 2010 | 128 | 0.040 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 223 | 0.040 |
Why?
| Pharmacists | 1 | 2019 | 143 | 0.040 |
Why?
| Drug Resistance, Bacterial | 1 | 2017 | 72 | 0.040 |
Why?
| Sensitivity and Specificity | 1 | 2019 | 858 | 0.040 |
Why?
| Vaccination | 1 | 2019 | 275 | 0.030 |
Why?
| Pilot Projects | 1 | 2019 | 702 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2017 | 271 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2019 | 1182 | 0.030 |
Why?
| Waist-Hip Ratio | 1 | 2015 | 6 | 0.030 |
Why?
| Radioimmunoassay | 1 | 2015 | 44 | 0.030 |
Why?
| Clavulanic Acids | 1 | 2014 | 8 | 0.030 |
Why?
| Ticarcillin | 1 | 2014 | 8 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2015 | 404 | 0.030 |
Why?
| Time Factors | 1 | 2020 | 2891 | 0.030 |
Why?
| Neisseria meningitidis | 1 | 2013 | 4 | 0.030 |
Why?
| Leukocyte Count | 1 | 2013 | 71 | 0.030 |
Why?
| Intensive Care Units | 1 | 2014 | 223 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2015 | 907 | 0.030 |
Why?
| DNA Primers | 1 | 2002 | 208 | 0.030 |
Why?
| Transcription, Genetic | 1 | 2002 | 370 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 409 | 0.020 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2002 | 189 | 0.020 |
Why?
| RNA, Messenger | 1 | 2002 | 1099 | 0.020 |
Why?
| Prognosis | 1 | 2013 | 1956 | 0.020 |
Why?
| Electric Stimulation | 1 | 2002 | 117 | 0.010 |
Why?
| Transcranial Magnetic Stimulation | 1 | 2002 | 69 | 0.010 |
Why?
| Cerebral Cortex | 1 | 2002 | 195 | 0.010 |
Why?
|
|
Romero's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|